Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03606460 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)
A Phase 3 study of Multiple Sclerosis, sponsored by Genentech.
- Completed
- Registry status
- Phase 3
- Development phase
- 141
- Enrollment target
- 5
- Study locations
NCT03606460 is a Phase 3 study of Multiple Sclerosis that has completed, run by Genentech. The registered enrollment target is 141 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (76% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT03606460, a Phase 3 study of Multiple Sclerosis, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 141 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is an open-label, non-randomized study to evaluate rate and severity of infusion-related reactions (IRRs) of ocrelizumab infused over a shorter time period than the approved administration rate in participants with PPMS or RMS in the United States (U.S.). Participants will be enrolled into two cohorts. Cohort 1 will examine the effect of administering ocrelizumab per a shorter infusion protocol for Dose 2 or Dose 3. This cohort will consist of patients who have already received one or two doses of ocrelizumab according to the approved infusion protocol (i.e., per the currently U.S. label) and have reported no serious IRRs and who will then receive the next infusion of ocrelizumab at a higher rate in order to deliver 600 mg over the course of approximately 2 hours. Cohort 2 will examine the effect of administering ocrelizumab per a shorter infusion protocol for the second infusion of Dose 1. This cohort will consist of ocrelizumab naïve patients who, after receiving Infusion 1/Dose 1 of ocrelizumab at the approved rate (300 mg over approximately 2.5 hours or longer) have no reported serious IRRs, will then receive the second 300-mg shorter infusion over approximately 1.5 hours.
Conditions Studied
Interventions
- DRUG Ocrelizumab Dose 1
- DRUG Ocrelizumab Dose 2 and Dose 3
Study Locations (5)
Ohio
- Cleveland Clinic Fndn - Cleveland
- Ohio Health Research Institute Grant Medical Center - Columbus
Colorado
- University of Colorado; Anschutz Medical Campus Department of Neurology - Aurora
Massachusetts
- Dragonfly Research, LLC - Wellesley
Oklahoma
- Oklahoma Medical Research Foundation; MS Center of Excellence - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2018-09-14 |
| Est. Completion | 2019-05-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03606460
The ClinicalTrials.gov registry entry for NCT03606460 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (76% lower). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Ocrelizumab Dose 1 is the first listed.
NCT03606460 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Ohio, Colorado, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03606460 about?
NCT03606460 is a clinical study titled "A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)". This study is an open-label, non-randomized study to evaluate rate and severity of infusion-related reactions (IRRs) of ocrelizumab infused over a shorter time period than the approved administration rate in participants with PPMS or RMS in the United States (U.S.). Participants will be enrolled int...
What is the current status of trial NCT03606460?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 141 participants. The study started on 2018-09-14. Estimated completion is 2019-05-31.
What conditions does trial NCT03606460 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT03606460?
The interventions under investigation include: Ocrelizumab Dose 1 (DRUG), Ocrelizumab Dose 2 and Dose 3 (DRUG).
Who is sponsoring clinical trial NCT03606460?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03606460 being conducted?
This trial has 5 study locations across Colorado, Massachusetts, Ohio, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
RECRUITING · Phase 3
-
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
RECRUITING · Phase 3
-
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
ACTIVE NOT RECRUITING · Phase 3
-
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.